Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - An analysis based on the ProGERD initiative

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 8, 2003, Pages 767-776

  Kulig, M ^a   Leodolter, A ^b   Vieth, M ^b   Schulte, E ^a   Jaspersen, D ^c   Labenz, J ^d   Lind, T ^e,f   Meyer Sabellek, W ^e,f   Malfertheiner, P ^b   Stolte, M ^g   Willich, S N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c KLINIKUM FULDA   (Germany)

^d Ev Jung Stilling Krankenhaus   (Germany)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

^g INSTITUTE OF PATHOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; ESOMEPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CLINICAL TRIAL; COHORT ANALYSIS; EMOTION; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; MULTIPLE REGRESSION; OPEN STUDY; PAIN; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SLEEP; SOCIAL INTERACTION;

ADULT; AGED; ANTI-ULCER AGENTS; COHORT STUDIES; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 10744229402     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01770.x     Document Type: Article

References (39)

1. Wiklund I, Butler-Wheelhouse P. Psychosocial factors and their role in symptomatic gastroesophageal reflux disease and functional dyspepsia. Scand J Gastroenterol Suppl 1996; 220: 94-100.
2. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 24-9.
3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21(11): 953-6.
4. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - The Genval Workshop Report. Gut 1999; 44(Suppl. 2): 1-16.
5. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340(11): 825-31.
6. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. Br Med J 2000; 321(7271): 1252-5.
7. Gudlaugsdottir S, van Blankenstein M, Dees J, et al. A majority of patients with Barrett's oesophagus are unlikely to benefit from endoscopic cancer surveillance. Eur J Gastroenterol Hepatol 2001; 13(6): 639-45.
8. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001; 111(1): 33-7.
9. Frank L, Kleinman L, Ganoczy D, McQuaid K, Sloan S. Upper gastrointestinal symptoms in North America: prevalence and relationship to health care utilization and quality of life. Dig Dis Sci 2000; 45: 809-18.
10. Henke CJ, Levin TR, Henning JM, Potter LP. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000; 95: 788-92.
11. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983; 78(5): 257-60.
12. Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28(8): 681-7.
13. Tebaldi M, Heading RC. Quality of life assessment in reflux disease. Eur J Gastroenterol Hepatol 1998; 10(6): 451-4.
14. Wiklund I, Bardhan KD, Muller-Lissner S, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol 1998; 30(1): 19-27.
15. Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104(3): 252-8.
16. Revicki DA, Crawley JA, Zodet MW, et al Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13(12): 1621-30.
17. Havelund T, Lind T, Wiklund I, et al Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94(7): 1782-9.
18. Eloubeidi MA, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus. Am J Gastroenterol 2000; 95(8): 1881-7.
19. Revicki DA, Sorensen S, Maton PN, et al Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16(5): 284-91.
20. Kulig M, Leodolter A, Nocon M, et al Patients with gastroesophageal reflux disease - design and first epidemiologic results of the ProGERD study. J Clin Epidemiol 2003 in press.
21. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45(2): 172-80.
22. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001; 96: 52-7.
23. Wiklund IK, Junghard O, Grace E, et al. Quality of Life in Reflux and Dyspepsia Patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998; 583: 41-9.
24. Talley NJ, Fullerton S, Junghard O, et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96(7): 1998-2004.
25. Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473-83.
26. Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey. Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
27. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Summary Scales: A User's Manual. Boston, MA: New England Medical Center, The Health Institute, 1994.
28. Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. Int Quality Life Assessment Soc Sci Med 1995; 41: 1359-66.
29. Guyatt GH, Juniper EF, Walter SD, et al. Interpreting treatment effects in randomised trials. Br Med J 1998; 316(7132): 690-3.
30. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res 1993; 2: 221-6.
31. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989; 27: 178-89.
32. Cohen J. Statistical Power Analysis for the Behavioural Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
33. Bullinger M, Kirchberger I. Der SF-36 Fragebogen zum Gesundheitszustand. Handbuch für die Deutschsprachige Fragebogenversion. Göttingen, Bern, Toronto, Seattle: Hogrefe Verlag für Psychologie. 1998.
34. Ware JE, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries. J Clin Epidemiol 1998; 51: 1167-70.
35. Hemingway H, Stafford M, Stansfeld S, et al. Is the SF-36 a valid measure of change in population health? Results from the Whitehall II Study. Br Med J 1997; 513: 1273-9.
36. Willich SN, Müller-Nordhorn J, Kulig M, et al. Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease - a prospective cohort study. Eur Heart J 2001; 22: 307-13.
37. Müller-Nordhorn J, Kulig M, Binting S. et al. for the PIN Study Group. Change in quality of life in the year following cardiac rehabilitation - is it clinically relevant and what are its predictors? Qual Life Res 2003 in press.
38. Velanovich V, Karmy-Jones R. Measuring gastroesophageal reflux disease: relationship between the health-related quality of life and physiologic parameters. Am Surg 1998; 64: 649-53.
39. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001; 161: 45-52.